Loading
A phase 2 trial of h101 oncolytic adenovirus and camrelizumab in pancreatic cancer, run by Fudan University, not yet recruiting.
Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT06196671 by Fudan University, with a registry enrolment figure of 30 participants, started 2026-12-01 and due to reach its primary completion in 2028-01-01. Interventions recorded: H101; Camrelizumab. Conditions listed: Pancreatic Cancer. Primary outcome: Overall survival，OS. Pancreatic eligibility wording from the registry: "* Histologically or cytologically confirmed advanced pancreas adenocarcinoma". No results are recorded here; the registry entry is the source.
Shares Camrelizumab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.